Skip to Content

SanBio Co Ltd ADR SNBOY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

There is no Morningtar’s Analysis data available.

Company Profile

Business Description

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

Contact
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku
Tokyo, 104-0044, Japan
T +81 362643481
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Apr 30, 2020
Fiscal Year End Jan 31, 2020
Stock Type
Employees 74